Answers are grounded in this paper and cite their sources.
Here we provide a review of available literature pertaining to these challenges in the 225Acradiopharmaceutical field and also provide insight into how performed and planned efforts at TRIUMF - Canada's particle accelerator centre - aim to address these issues.
No takes yet. Share an insight, caveat, or question.
Robertson et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: